TF
Therapeutic Areas
Artivion Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AMDS Hybrid Prosthesis | Acute DeBakey Type I Aortic Dissection with Malperfusion | Pivotal (HDE Approved) |
| On-X Aortic Heart Valve | Real-world outcomes with Low Dose Anticoagulation | Post-Market Study |
Leadership Team at Artivion
JP
J. Patrick Mackin
Chairman, President & CEO
JF
Jean F. Holloway
VP, General Counsel & Corporate Secretary
DA
D. Ashley Lee
EVP, CFO & COO
JP
John P. (Pat) Hussey
VP, Global Operations
LL
Lindsay L. Weber
VP, Human Resources
TJ
Todd J. Sheeran
VP, Global Sales
SL
S. Lance Bussang
VP, Corporate Development & Strategy
JW
James W. Bullock
VP, Global Marketing & Education
MR
Matthew R. Stultz
VP, Global Clinical & Regulatory Affairs
JJ
John J. Arlotta
Lead Independent Director